Why the study?
To evaluate the association of delivery hospitalization NT-proBNP concentration with persistent postpartum hypertension and postpartum blood pressure trajectory in individuals with hypertensive disorders of pregnancy.
Does high NT-proBNP at delivery predict persistent postpartum hypertension in individuals with hypertensive disorders of pregnancy?
Does high NT-proBNP at delivery predict persistent postpartum hypertension in individuals with hypertensive disorders of pregnancy?
Elevated NT-proBNP (≥150 pg/mL) at the time of delivery in individuals with hypertensive disorders of pregnancy is associated with a significantly higher risk of persistent postpartum hypertension at 6 weeks.
Answers are grounded in this paper and cite their sources.
High NT-proBNP at delivery may warrant closer postpartum monitoring; extends risk stratification in hypertensive pregnancy but remains hypothesis-generating.
This study aimed to evaluate the association of N-terminal pro B-type natriuretic peptide (NT-proBNP) concentration during the delivery hospitalization with persistence of postpartum hypertension and postpartum blood pressure (BP) trajectory among individuals with hypertensive disorders of pregnancy (HDP). This was a single-site cohort study including individuals with new-onset HDP who participated in a remote BP monitoring program and an obstetric biobank. Postpartum BP data were collected from the delivery hospitalization, remote monitoring program, and outpatient visits. Correlations between log(NT-proBNP) and BP values were assessed, and outcomes were compared between low-NT-proBNP (defined as less than 150 pg/mL based on previously published reference intervals in pregnancy) and high-NT-proBNP (greater than or equal to 150 pg/mL) groups. A total of 111 individuals were included, with 31 (27.9%) in the low-NT-proBNP group and 80 (72.1%) in the high-NT-proBNP group. Log(NT-proBNP) had a weakly positive correlation with maximum postpartum systolic (SBP) and diastolic BP (DBP) during the delivery hospitalization. Persistent postpartum hypertension, defined as antihypertensive medication or stage two hypertension at 6 weeks postpartum, occurred in 40.0% of the high-NT-proBNP group versus 19.4% of the low-NT-proBNP group (p = 0.04). The high-NT-proBNP group also had significantly different maximum postpartum DBP during the delivery hospitalization (101 vs. 94 mm Hg, p = 0.01), maximum SBP during remote monitoring (145 vs. 139 mm Hg, p = 0.049), and likelihood of being on antihypertensive medication at 6 weeks postpartum (31.3 vs. 12.9%, p = 0.048) and at any time between delivery and 6 weeks postpartum (48.8 vs. 22.6%, p = 0.01) compared with the low-NT-proBNP group. The high- versus low-NT-proBNP groups had significantly different SBP trajectories over the first 14 days postpartum, with the greatest difference noted in the first 3 to 4 days. NT-proBNP measurement among individuals with HDP at the time of delivery may be useful in assessing risk for persistent postpartum hypertension.
No takes yet. Share an insight, caveat, or question.
Shay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: